Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo

1. Mulligan, R.C. 1993. The basis science of gene therapy. Science 260: 926−932.
2. Crystal, R.G. 1995. Transfer of genes to humans: early lessons and obstacles to success. Science 270: 404−410.
3. Leiden, J.M. 1995. Gene therapy—promises, pitfalls and prognosis. N. Engl. J. Med. 333: 871−873.
4. Sanders, W.R. 1995. Human gene therapy—of tortoises and hares. Nature Medicine 1: 1137−1138.
5. Roe, T., Reynolds, T.C., Yu, G., and Brown, P.O. 1993. Integration of murine leukemia virus DNA depends on mitosis. EMBO J. 12: 2099−2108.
6. Lewis, P.F. and Emerman, M. 1994. Passage through mitosis is required for oncoretroviruses but not for the human immunodeficiency virus. J. Virol. 68: 510−516.
7. Lewis, P., Hensel, M., and Emerman, M. 1992. Human immunodeficiency virus infection of cell arrested in the cell cycle. EMBO J. 11: 3053−3058.
8. Bukrinsky, M.I., Haggerty, S., Dempsey, M.P., Sharova, N., Adzhubei, A., Spitz, L., et al. 1993. A nuclear localization signal within HIV-1 matrix protein that governs infection of non-dividing cells. Nature 365: 666−669.
9. von Schwedler, U., Kornbluth, R.S., and Trono, D. 1994. The nuclear localization signal of the matrix protein of human immunodeficiency virus type 1 allows the establishment of infection in macrophages and quiescent T lymphocytes. Proc. Natl. Acad. Sci. USA 91: 6992−6996.
10. Gallay, P., Stitt, V., Mundy, C., Oettinger, M., and Trono, D. 1996. Role of the karyopherin pathway in human immunodeficiency type 1 nuctear import. J. Virol. 70: 1027−1032.
11. Naldini, L., Blömer, U., Gallay, P., Ory, D., Mulligan, R.C., Gage, F.H., et al. 1996. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 272: 263−267.
12. Naldini, L., Blömer, U., Gage, F.H., Trono, D. and Verma, I.M. 1996. Efficient transfer, integration, and sustained long-term expression of the transgene in adult rat brains injected with a lentiviral vector. Proc. Natl Acad. Sci. USA 93: 11382−11388.
13. Trono, D. 1995. HIV accessory proteins: leading role for the supporting cast. Cell 82: 189−192.
14. Miller, R.H. and Sarver, N. 1997. HIV accessory proteins as therapeutic targets. Nature Medicine 3: 389−394.
15. Gheysen, D. et al. 1989. Assembly and release of HIV-1 precursor Pr55^gag virus-like particles from recombinant baculovirus-infected insect cells. Cell 59: 103−112.
16. Heinzfriger, N.K., Bukrinsky, M.I., Haggerty, S.A., Ragland, A.M., Kewalramani, V., Lee, M.A., et al. 1994. The Vpr protein of human immunodeficiency virus type 1 influences nuctear localization of viral nudefc acids in nondividing host cells. Proc. Natl. Acad. Sci. USA 91: 7311−7315.
17. Gabuzda, D.H., Lawrence, K., Langhoff, E., Terwilliger, E.F., Dorfman, T., Haseltine, W.A., et al. 1992. Role of vif in replication of human immunodeficiency virus type 1 in CD4⁺ T lymphocytes. J. Virol. 66: 6489−6495.
18. von Schwedler, U., Song, J., Aiken, C., and Trono, D. 1993. vif is crucial for human immunodeficiency virus type 1 proviral DNA synthesis in infected cells. J. Virol. 67: 4945−4955.
19. Klimkait, T., Strebel, K., Hoggan, M.D., Martin, M.A., and Orenstein, J.M. 1990. The human immunodeficiency virus type 1-specific protein vpu is required for efficient virus maturation and release. J. Virol. 64: 621−629.
20. Göttlinger, H.G., Dorfman, T., Cohen, E., and Haseltine, W.A. 1993. Vpu protein of human immunodeficiency virus type 1 enhances the release of capsids produced by gag gene constructs of widely divergent retroviruses. Proc. Natl. Acad. Sci. USA 90: 7381−7385.
21. Miller, M.D., Warmerdam, M.T., Gaston, I., Greene, W.C., and Feinberg, M.B. 1994. The human immunodeficiency virus-1 nef gene product: a positive factor for viral infection and replication in primary lymphocytes and macrophages. J. Exp. Med. 179: 101−113.
22. Spina, C.A., Kwoh, T.J., Chowers, M.Y., Guatelli, J.C., and Richman, D.D. 1994. The importance of nef in the induction of human immunodeficiency virus type 1 replication from primary quiescent CD4 lymphocytes. J. Exp. Med. 179: 115−123.
23. Aiken, C. and Trono, D. 1995. Nef stimulates human immunodeficiency virus type 1 proviral DNA synthesis. J. Virol. 69: 5048−5056.
24. Schwartz, O., Marechal, V., Danos, O., and Heard, J.-M. 1995. Human immunodeficiency virus type 1 Nef increases the efficiency of reverse transcription in the infected cell. J. Virol. 69: 4053−1059.
25. Chowers, M.Y., Pandori, M.W., Spina, C.A., Richman, D.D., and Guatelli, J.C. 1995. The growth advantage conferred by HIV-1 nef is determined at the level of viral DNA formation and is independent of CD4 downregulation. Virology 212: 451−457.
26. Aiken, C. 1997. Pseudotyping human immunodeficiency virus type 1 (HIV-1) by the glycoprotein of vesicular stomatitis virus targets HIV-1 entry to an endocytic pathway and suppresses both the requirement for Nef and the sensitivity to cyclosporin A. J. Virol. 71: 5871−5877.
27. Gallay, P., Chin, D., Hope, T.J., and Trono, D. HIV-1 infection of nondividing cells mediated through the recognition of integrase by the importin/karyopherin pathway. Proc. Natl. Acad. Sci. USA. In press.
28. Levy, D.N., Fernandes, L.S., Williams, W.V., and Weiner, D.B. 1993. Induction of cell differentiation by human immunodeficiency virus 1 vpr. Cell 72: 541−550.
29. Rogel, M.E., Wu, L.I., and Emerman, M. 1995. The human immunodeficiency virus type 1 vpr gene prevents cell proliferation during chronic infection. J. Virol. 69: 882−888.
30. Kirchhoff, F., Greenough, T.C., Brettler, D.B., Sullivan, J.L., and Desrosiers, R.C. 1995. Absence of intact nef sequences in a long-term survivor with nonprogressive HIV-1 infection. N. Engl. J. Med. 332: 228−232.
31. Deacon, N.J., Tsykin, A., Solomon, A., Smith, K., Ludford-Menting, M., Hooker, D.J., et al. 1995. Genomic structure of an attenuated quasi species of HIV-1 from a blood transfusion donor and recipients. Science 270: 988−991.
32. Kestler, H.W. III, Ringler, D.J., Mori, K., Panicali, D.L., Sehgal, P.K., Daniel, M.D., et al. 1991. Importance of the nef gene for maintenance of high virus loads and for development of AIDS. Cell 65: 651−662.
33. Daniel, M.D., Kirchhoff, F., Czajak, S.C., Sehgal, P.K., and Desrosiers, R.C. 1992. Protective effect of a live-attenuated SIV vaccine with a deletion in the nef gene. Science 258: 1938−1941.
34. Wyand, M.S., Manson, K.H., Lackner, A.A., and Desrosiers, R.C. 1997. Resistance of neonatal monkeys to live attenuated vaccine strains of simian immunodeficiency virus. Nature Medicine 3: 32−36.
35. Gibbs, J.S., Regier, D.A., and Desrosiers, R.C. 1994. Construction and in vitro properties of SIVmac mutants with deletions in "nonessential" genes. AIDS Res. Hum. Retrovir. 10: 607−616.
36. Park, I.-W., Myrick, K., and Sodroski, J. 1994. Effects of vif mutations on cell-free infectivity and replication of simian immunodeficiency virus. J. AIDS 7: 1228−1236.
37. Lang, S.M., Strahl-Hennig, C., Coulibaly, C., Hunsmann, G., Muller, J., Muller-Hermalink, H., et al. 1993. Importance of vpr for infection of rhesus monkey with simian immunodeficiency virus. J. Virol. 67: 902−912.
38. Fletcher, T.M., Brichacke, B., Sharova, N., Newman, M.A., Stivahtis, G., Sharp, P.M., et al. 1997. Nuclear import and cell cycle arrest functions of the HIV-1 Vpr protein are encoded by two separate genes in HIV-2/SIV. EMBO J. 15: 6155−6165.
39. Wang, B., Ge, Y.C., Palasanthiran, P., Xiang, S., Ziegler, J., Dwyer, D.E., et al. 1996. Gene defects clustered at the C-terminus of the vpr gene of HIV-1 in long-term nonprogressing mother and child pair: in vivo evolution of vpr quasispcies in blood and plasma. Virology 223: 224−232.
40. Brach, M.A., Hass, R., Sherman, M.L., Gunji, H., Weichselbaum, R., and Kufe, D. 1991. Ionizing radiation induces expression and binding activity of the Nuclear Factor B. J. Clin. Invest. 88: 691−695.

	Top

	Top